6. FEJEZET | HIVATKOZÁSOK

  1. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.
  2. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
  3. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-684.
  4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25-32.
  5. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038-2044.
  6. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-420.
  7. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41-44.
  8. Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018;2(16):2136-2144.
  9. Collins PW, Young G, Knobe K, et al. Recombinant long-acting gly- coPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880-3886.
  10. Kruse-Jarres R, Oldenburg J, Santagostino E, et al. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019;25(2):213-220.
  11. Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25(6):979-987.
  12. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
  13. Andersson NG, Auerswald G, Barnes C, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B–the impact of prophylactic treatment. Br J Haematol. 2017;179(2):298-307.
  14. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99(7):2337-2341.
  15. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. B r J Haematol. 1999;105(4):1109-1113.
  16. Oldenburg J, Zimmermann R, Katsarou O, et al. Controlled, crosssectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia. 2015;21(2):171-179.
  17. Fischer K, Collins PW, Ozelo MC, Srivastava A, Young G, Blanchette VS. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(5):1105-1109.
  18. Feldman BM, Rivard GE, Babyn P, et al. Tailored frequency- escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol. 2018;5(6):e252-e260.
  19. Nijdam A, Kurnik K, Liesner R, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia. 2015;21(4):444-450.
  20. Gouider E, Jouini L, Achour M, et al. Low dose prophylaxis in Tunisian children with haemophilia. Haemophilia. 2017;23(1):77-81.
  21. Lj ung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol. 2015;169(6):777-786.
  22. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-4055.
  23. Barg AA, Avishai E, Budnik I, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors–a single- center cohort. Pediatr Blood Cancer. 2019;66(11):e27886.
  24. Pierce GF, Hart DP, Kaczmarek R, WFH Coagulation Product Safety, Supply, and Access (CPSSA) Committee of the World Federation of Hemophilia (WFH). Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia. 2019;25(5):e33 4-e335.
  25. Fischer K, Steen Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122(7):1129-1136.
  26. Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368-2374.
  27. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73(5):691-701.
  28. Khair K, Ranta S, Thomas A, Lindvall K. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia. 2017;23(4):e276-e281.
  29. Carcao MD, Iorio A. Individualizing factor replacement therapy in severe hemophilia. Semin Thromb Hemost. 2015;41(8):864-871.
  30. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New Engl J Med. 2013;369(24):2313-2323.
  31. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX- FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761-1769.
  32. Oldenburg J, Carcao M, Lentz SR, et al. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of

15% in patients with haemophilia B: pooled data from the paradigm trials. Haemophilia. 2018;24(6):911-920.

  1. Cooley B, Broze GJ Jr, Mann DM, Lin FC, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood. 2019;133(22):2445-2451.
  2. Malec LM, Croteau SE, Callaghan MU, Sidonio RF Jr. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres. Haemophilia. 2020. [published online ahead of print, March 6, 2020] https://doi.org/10.1111/hae.13943
  3. Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267-e274.
  4. Stafford DW. Extravascular FIX and coagulation. Thromb J. 2016;14(Suppl 1):35.
  5. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20:99-105.
  6. Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer-l asting and more effective therapeutics. Crit Rev Biotechnol. 2013;35(2):235-254.
  7. Metzner HJ, Pipe SW, Weimer T, Schulte S. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost. 2013;110(5):931-939.
  8. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, nonrandomised phase 3 study. Lancet Haematol. 2019;6(6):e295-e305.
  9. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
  10. Komvilaisak P, Connolly B, Naqvi A, Blanchette V. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia. 2006;12:87-93.
  11. Chozie NA, Primacakti F, Tulaar A, Setiabudy R, Prasetyo M, Gatot D. Low-dose prophylaxis versus on-demand treatment in Indonesian children with severe hemophilia A: an interim report [M-P-100 (95) abstract]. Haemophilia. 2018;24(S5).
  12. Chozie NA, Primacakti F, Gatot D, Setiabudhy RD, Tulaar ABM, Prasetyo M. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children. Haemophilia. 2019;25(4):633-639.
  13. Tang L, Wu R, Sun J, et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia. 2013;19(1):27-34.
  14. Verma SP, Dutta TK, Mahadevan S, et al. A randomized study of very low-dose factor VIII prophylaxis in severe haemophil- ia–a success story from a resource limited country. H aemophilia. 2016;22(3):342-348.
  15. WAPPS-Hemo Research Network. WAPPS-Hemo. Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo). WAPPS-Hemo website. Hamilton, ON: McMaster University. https://www.wapps-hemo.org. Hozzáférés: 2020. április 24.
  16. Ljung R, Auerswald G, Benson G, et al. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia. 2013;19(4):481-486.
  17. Brummel-Ziedins KE, Wolberg AS. Global assays of hemostasis. Curr Opin Hematol. 2014;21(5):395-403.
  18. van Dijk K, van der Bom J, Lenting P, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica. 2005;90(4):494-498.
  19. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia. 2005;11(5):438-443.
  20. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr. 1999;158(Suppl 3):S166-S170.
  21. Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia. 2010;16(Suppl 2):4-9.
  22. Lee Mortensen G, Strand AM, Almen L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review. Haemophilia. 2018;24(6):862-872.
  23. O’Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia. 2015;21(4):436-443.
  24. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia. 1998;4(4):474-480.
  25. Srivastava A. Factor replacement therapy in haemophilia–are there models for developing countries? Haemophilia. 2003;9(4):391-396
  26. Gouider E, Rauchensteiner S, Andreeva T, et al. Real-life evidence in evaluating effectiveness of treatment in haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries. Haemophilia. 2015;21(3):e167-e175.
  27. Tang L, Xu W, Li CG, et al. Describing the quality of life of boys with haemophilia in China: results of a multicentre study using the CHO- KLAT. Haemophilia. 2018;24(1):113-119.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.